Vir Biotechnology (VIR) Return on Capital Employed (2019 - 2026)
Vir Biotechnology (VIR) reported Return on Capital Employed of 50.19% for Q1 2026, up 299.0% on a YoY basis from 12.58% in Q1 2025, and up 3.85% sequentially from 52.2% in Q4 2025.
Vir Biotechnology (VIR) Return on Capital Employed (2019 - 2026) Analysis & Trends
Vir Biotechnology (VIR) has 8 years of Return on Capital Employed data on file, last reported at 50.19% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 299.0% year-over-year to 50.19%; the trailing twelve-month figure through Mar 2026 stood at 50.19% (up 299.0% YoY), and the FY2025 full-year result was 43.26%, down 511.0% from the prior year.
- Return on Capital Employed rose to 50.19% in Q1 2026, from 52.2% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 92.72% in Q1 2022 to a low of 53.22% in Q3 2025.
- A 5-year average of 15.6% and a median of 35.24% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 15032 bps in 2022 and plunged 10713 bps in 2023, its largest moves.
- Tracing VIR's Return on Capital Employed over 5 years: stood at 37.22% in 2022, then tumbled by 202 bps to 37.88% in 2023, then slipped by 17 bps to 44.18% in 2024, then declined by 18 bps to 52.2% in 2025, then advanced by 4 bps to 50.19% in 2026.
- Business Quant data shows VIR's Return on Capital Employed at 50.19% in Q1 2026, 52.2% in Q4 2025, and 53.22% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Vir Biotechnology | 1.38 Bn | 1.38 Bn | - | -50.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.19% |
| Dec 31, 2025 | -52.20% |
| Sep 30, 2025 | -53.22% |
| Jun 30, 2025 | -52.96% |
| Mar 31, 2025 | -53.18% |
| Dec 31, 2024 | -44.18% |
| Sep 30, 2024 | -41.52% |
| Jun 30, 2024 | -34.52% |
| Mar 31, 2024 | -35.24% |
| Dec 31, 2023 | -37.88% |
| Sep 30, 2023 | -35.15% |
| Jun 30, 2023 | -14.09% |
| Mar 31, 2023 | -14.41% |
| Dec 31, 2022 | 37.22% |
| Sep 30, 2022 | 66.20% |
| Jun 30, 2022 | 57.44% |
| Mar 31, 2022 | 92.72% |
| Dec 31, 2021 | 33.90% |
| Sep 30, 2021 | -28.82% |
| Jun 30, 2021 | -30.89% |